Epoch Investment Partners Inc. Trims Stock Position in Medpace Holdings, Inc. $MEDP

Epoch Investment Partners Inc. lowered its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 77.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 28,958 shares of the company’s stock after selling 96,743 shares during the period. Epoch Investment Partners Inc.’s holdings in Medpace were worth $16,264,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. BOKF NA raised its stake in shares of Medpace by 0.8% during the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after buying an additional 20 shares during the last quarter. Valeo Financial Advisors LLC raised its stake in shares of Medpace by 5.0% during the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after buying an additional 21 shares during the last quarter. UMB Bank n.a. raised its stake in shares of Medpace by 5.6% during the 4th quarter. UMB Bank n.a. now owns 450 shares of the company’s stock valued at $253,000 after buying an additional 24 shares during the last quarter. Schulhoff & Co. Inc. raised its stake in shares of Medpace by 1.1% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after buying an additional 25 shares during the last quarter. Finally, Kaufman Rossin Wealth LLC raised its stake in shares of Medpace by 3.4% during the 4th quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock valued at $447,000 after buying an additional 26 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Activity

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This represents a 67.88% decrease in their position. The disclosure for this sale is available in the SEC filing. 20.50% of the stock is owned by insiders.

Medpace Price Performance

Shares of Medpace stock opened at $467.34 on Monday. Medpace Holdings, Inc. has a twelve month low of $294.07 and a twelve month high of $628.92. The business has a 50-day moving average price of $456.43 and a 200 day moving average price of $503.84. The firm has a market cap of $13.35 billion, a PE ratio of 29.37, a P/E/G ratio of 2.37 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. During the same quarter in the previous year, the business earned $3.67 EPS. Medpace’s revenue for the quarter was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on MEDP. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and reduced their price objective for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Barclays reduced their price objective on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research note on Friday, April 24th. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. BMO Capital Markets reduced their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research note on Friday, April 24th. Finally, Robert W. Baird reduced their price objective on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $467.08.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.